Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.83 |
| ▸ | GUSB | P08236 | 8/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1250496 | 0.93 | DGAT1 (0.80) | DGAT1GUSBCHEK2 | |
| SCHEMBL30385298 | 0.91 | DGAT1 (1.00) | DGAT1GUSBCHEK2 | |
| SCHEMBL1252216 | 0.91 | DGAT1 (1.00) | DGAT1GUSBCHEK2 | |
| SCHEMBL13695119 | 0.90 | DGAT1 (0.69) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL10299680 | 0.85 | DGAT1 (0.62) | DGAT1GUSB | |
| SCHEMBL1252823 | 0.83 | DGAT1 (0.66) | DGAT1GUSBCHEK2 | |
| SCHEMBL1252747 | 0.83 | DGAT1 (0.85) | DGAT1GUSBKDM4EALDH1A1HPGD | |
| SCHEMBL31326547 | 0.82 | DGAT1 (0.83) | DGAT1CHEK2 | |
| SCHEMBL1252030 | 0.82 | DGAT1 (0.83) | DGAT1CHEK2 | |
| SCHEMBL1252829 | 0.81 | DGAT1 (0.64) | DGAT1GUSBMMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217065-B2 | Organic compounds | NOVARTIS AG (SE) | 2012-07-10 | — | — | US | disclosed |
| US-20110077277-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077277-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885GUSB 217/4885MMP2 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.